Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2017
18th World Conference on Lung Cancer
Access to all presentations that occur during the 18th World Conference on Lung Cancer in Yokohama, Japan
Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Download PDF of the Conference Program: Click Here.
Presentations will be available 24 hours after their live presentation time
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
-
+
MTE 28 - Immunotherapy for Earlier Stage NSCLC (Sign Up Required)
- Type: Meet the Expert
- Track: Immunology and Immunotherapy
- Presentations: 2
- Coordinates: 10/18/2017, 07:00 - 08:00, Room 301 + 302
-
+
MTE 28.01 - Rationale for IO in Treatment of Early Stage NSCLC
07:00 - 07:30 | Presenter: Patrick M Forde
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE 28.02 - Pros and Cons of IO in Early Stage NSCLC
07:30 - 08:00 | Presenter: Edward Brian Garon
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 29 - Stereotactic Body Radiation Therapy for Early Stage Lung Cancer (Sign Up Required)
- Type: Meet the Expert
- Track: Radiotherapy
- Presentations: 1
- Coordinates: 10/18/2017, 07:00 - 08:00, Room 502
-
+
MTE 29.01 - Update and Overview of SBRT for Early Stage Lung Cancer
07:00 - 08:00 | Presenter: Yasushi Nagata
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 30 - Surgery after Concurrent Chemoradiotherapy (Sign Up Required)
- Type: Meet the Expert
- Track: Surgery
- Presentations: 1
- Coordinates: 10/18/2017, 07:00 - 08:00, Room 503
-
+
MTE 30.01 - Surgery after Concurrent Chemoradiotherapy
07:00 - 08:00 | Presenter: G. Lyons
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 31 - Perspectives of Anti-Angiogenesis (Sign Up Required)
- Type: Meet the Expert
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Coordinates: 10/18/2017, 07:00 - 08:00, Room 418
-
+
MTE 31.01 - Perspectives of Anti-Angiogenesis
07:00 - 08:00 | Presenter: John V Heymach
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
SH 03 - WCLC 2017 Highlights of the Previous Day
- Type: Scientific Highlights
- Track: Advanced NSCLC
- Presentations: 3
- Coordinates: 10/18/2017, 07:00 - 08:00, F201 + F202 (Annex Hall)
-
+
SH 03.01 - Advanced NSCLC and Immunology and Immunotherapy
07:00 - 07:20 | Presenter: Nico Van Zandwijk
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
SH 03.02 - Early Stage NSCLC and Radiology/Staging/Screening
07:20 - 07:40 | Presenter: Jaroslaw Kuzdzal
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
SH 03.03 - Biology/Pathology and Epidemiology/Primary Prevention/Tobacco Control and Cessation
07:40 - 08:00 | Presenter: Anja C Roden
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
SH 04 - WCLC 2017 Highlights of the Previous Day
- Type: Scientific Highlights
- Track: Biology/Pathology
- Presentations: 3
- Coordinates: 10/18/2017, 07:00 - 08:00, F203 + F204 (Annex Hall)
-
+
SH 04.01 - Chemotherapy/Targeted Therapy, Nursing/Palliative Care/Ethics and SCLC/Neuroendocrine Tumors
07:00 - 07:20 | Presenter: Paul Baas
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
SH 04.02 - Locally Advanced NSCLC & Radiotherapy
07:20 - 07:40 | Presenter: Fumihiro Tanaka
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
SH 04.03 - Biology/Pathology and Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
07:40 - 08:00 | Presenter: Kenzo Hiroshima
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Communication Skills Workshop (not public)
- Type: Workshop
- Track:
- Presentations: 1
- Coordinates: 10/18/2017, 08:00 - 14:00, Room 317
-
+
Communication Techniques
08:00 - 08:40 | Presenter: J. Carter
- Abstract
No abstract available for this presentation
-
+
PL 03 - Immunology in Lung Cancer Update 2017
- Type: Plenary Session
- Track: Immunology and Immunotherapy
- Presentations: 4
- Moderators:David P Carbone
- Coordinates: 10/18/2017, 08:15 - 09:45, Plenary Hall (Exhibit Hall D)
-
+
PL 03.01 - Serendipities of Acquired Immunity
08:15 - 08:45 | Presenter: Tasuku Honjo
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PL 03.02 - Biomarkers in Immunooncology Therapy
08:45 - 09:05 | Presenter: Naiyer Rizvi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PL 03.03 - Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples
09:05 - 09:25 | Presenter: Ming Sound Tsao
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PL 03.04 - Current Status and Future of Immunotherapy in Lung Cancer
09:25 - 09:45 | Presenter: Martin Reck
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.01 - Advanced NSCLC
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 97
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.01-001 - Comparisons of Two Plasma EGFR Platforms (ddPCR and Cobas) in Patients with Radiological Metastatic Lung Cancer
09:30 - 09:30 | Presenter: Jacky Yu Chung Li
- Abstract
Loading... -
+
P3.01-002 - Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient with EGFR TKI Drug Resistance
09:30 - 09:30 | Author(s): S. Xu
- Abstract
Loading... -
+
P3.01-003 - Study of the Relationship between EGFR Mutation Status and Bone Metastasis in Advanced Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Zhao Bing
- Abstract
Loading... -
+
P3.01-004 - The Underestimated Role of Bronchial Washing Fluid in the Detection of EGFR Mutation from Lung Cancer Patients
09:30 - 09:30 | Author(s): X. Zhang
- Abstract
Loading... -
+
P3.01-005 - ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis
09:30 - 09:30 | Presenter: Sang-We Kim
- Abstract
Loading... -
+
P3.01-006 - Osimertinib in Pretreated EGFR T790M-Positive Non-Small Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
09:30 - 09:30 | Presenter: Bin-Chi Liao
- Abstract
Loading... -
+
P3.01-007 - Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations
09:30 - 09:30 | Presenter: Edyta Maria Urbanska
- Abstract
Loading... -
+
P3.01-008 - Association between Icotinib Efficacy and Circulating Tumor Cell Levels in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): Y. Huang
- Abstract
Loading... -
+
P3.01-009 - Clinical Efficacy of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 18 E709X Mutations
09:30 - 09:30 | Author(s): Chunwei Xu
- Abstract
Loading... -
+
P3.01-010 - High Probability and Frequency of EGFR Mutations in Non-Small Cell Lung Cancer with Brain Metastases
09:30 - 09:30 | Author(s): M. Ge
- Abstract
Loading... -
+
P3.01-011 - Comparision of EGFR and ALK-Driven Lung Adenocarcinoma with Brain Metastases for Prognostic Factors in Chinese Patients
09:30 - 09:30 | Presenter: Fengnan Wang
- Abstract
Loading... -
+
P3.01-012 - Symptom Impact of First-Line Dacomitinib versus Gefitinib in EGFR-Positive NSCLC: Results from a Randomized Phase 3 Study
09:30 - 09:30 | Author(s): M.R. Migliorino
- Abstract
Loading... -
+
P3.01-013 - CNS Metastases in EGFR Mutation Positive NSCLC: Impact on Health Resource Utilization
09:30 - 09:30 | Presenter: Negar Chooback
- Abstract
Loading... -
+
P3.01-015 - Differential Outcomes between First and Second Generation TKIs in Patients with Activating EGFR Mutations in NSCLC
09:30 - 09:30 | Presenter: Sally C Lau
- Abstract
Loading... -
+
P3.01-016 - Factors Associated with Symptoms Improvement and HRQoL for First-Line EGFR-TKIs in NSCLC: A Multicenter Prospective SMILE Study
09:30 - 09:30 | Presenter: Yu-Feng Wei
- Abstract
Loading... -
+
P3.01-017 - Clinical Outcomes of Patients with EGFR T790M + NSCLC on Osimertinib
09:30 - 09:30 | Presenter: Wan Ling Tan
- Abstract
Loading... -
+
P3.01-018 - Mutation Abundance Affects the Therapeutic Efficacy of EGFR-TKI in Patients with Advanced Lung Adenocarcinoma: A Retrospective Analysis
09:30 - 09:30 | Presenter: Huijuan Wang
- Abstract
Loading... -
+
P3.01-019 - Canadian Multicentre Validation Study of Plasma Circulating Tumour DNA for Epidermal Growth Factor (EGFR) T790M Testing
09:30 - 09:30 | Presenter: Ming Sound Tsao
- Abstract
Loading... -
+
P3.01-020 - Clinical Features of Patients with Non-Small Cell Lung Cancer (NSCLC) Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations in Brunei
09:30 - 09:30 | Presenter: Shir Kiong Lu
- Abstract
Loading... -
+
P3.01-021 - A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIB/IV NSCLC in Northern China
09:30 - 09:30 | Presenter: Ying Cheng
- Abstract
Loading... -
+
P3.01-022 - Prognostic Value of Clinical, Immune and Biochemical Markers in EGFR-Mutant NSCLC Patients Treated with First-Line EGFR TKIs
09:30 - 09:30 | Presenter: Isaac Kah Siang Ng
- Abstract
Loading... -
+
P3.01-023 - First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice
09:30 - 09:30 | Presenter: Youjin Kim
- Abstract
Loading... -
+
P3.01-024 - Characterization of PD-L1 Expression and Its Predictive and Prognostic Significance in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs
09:30 - 09:30 | Presenter: Tao Jiang
- Abstract
Loading... -
+
P3.01-025 - Treatment Outcomes of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status: A Retrospective Analysis of 140 Patients
09:30 - 09:30 | Presenter: Cheng Xiao
- Abstract
Loading... -
+
P3.01-026 - Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC
09:30 - 09:30 | Presenter: Martin Schuler
- Abstract
Loading... -
+
P3.01-027 - TET2 Mutation as a Novel Mechanism of Acquired Resistance to EGFR TKIs Identified by a Mutational Profiling Using NGS
09:30 - 09:30 | Author(s): Y. Jin
- Abstract
Loading... -
+
P3.01-028 - Efficacy of Osimertinib for Brain Metastasis in Advanced NSCLC: Data from Single Center in ASTRIS Trial
09:30 - 09:30 | Presenter: Jee Hung Kim
- Abstract
Loading... -
+
P3.01-029 - Transient Asymptomatic Pulmonary Opacities (TAPOs) during Osimertinib Treatment and Its Clinical Implication
09:30 - 09:30 | Presenter: Hansang Lee
- Abstract
Loading... -
+
P3.01-030 - CNS Metastases in EGFR Mutation Positive (EGFRm) NSCLC Patients: The Prognostic Relevance of Presenting Symptoms
09:30 - 09:30 | Presenter: Negar Chooback
- Abstract
Loading... -
+
P3.01-031 - ctDNA Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non–Small-Cell Lung Cancer in Read World Setting
09:30 - 09:30 | Presenter: Shirong Zhang
- Abstract
Loading... -
+
P3.01-032 - Preliminary study of Lung Cancer Adenocarcinoma with De-novo EGFR T790M Mutation in Persahabatan Hospital-Jakarta, Indonesia.
09:30 - 09:30 | Presenter: Hapsari Dewanti
- Abstract
Loading... -
+
P3.01-033 - Detection of Epidermal Growth Factor Receptor Mutations with Plasma Sample Compared with Tumor Tissue Biopsy in Advanced Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Taewon Jang
- Abstract
Loading... -
+
P3.01-034 - Liquid Biopsy for EGFR Genotyping Using Cell-Free DNA and Extracellular Vesicular DNA of Pleural Effusion in Pulmonary Adenocarcinoma Patients
09:30 - 09:30 | Presenter: Jong Sik Lee
- Abstract
Loading... -
+
P3.01-035 - Post-Marketing Observational Study of Japanese Patients with EGFR Mutation-Positive (EGFRm+) NSCLC Treated with Daily Afatinib (Final Report)
09:30 - 09:30 | Presenter: Nobuyuki Yamamoto
- Abstract
Loading... -
+
P3.01-036 - A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis
09:30 - 09:30 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P3.01-037 - Understanding Mechanisms of Resistance to Osimertinib by Circulating Tumor DNA Genotyping in Advanced Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): Y. Du
- Abstract
Loading... -
+
P3.01-038 - Impact on OS and PFS of 2nd and 3rd Generation TKI in EGFR Mt+ and ALK+ Patients: Results of the NOWEL Network
09:30 - 09:30 | Presenter: Julia Roeper
- Abstract
Loading... -
+
P3.01-040 - Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US
09:30 - 09:30 | Author(s): Y. Li
- Abstract
Loading... -
+
P3.01-041 - The Robustness of Allele-Specific qPCR Assays for Detection of EGFR Mutations in Plasma Cell-Free DNA from NSCLC Patients
09:30 - 09:30 | Author(s): A. Szpechcinski
- Abstract
Loading... -
+
P3.01-042 - Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study
09:30 - 09:30 | Presenter: Thanyanan Reungwetwattana
- Abstract
Loading... -
+
P3.01-043 - Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung
09:30 - 09:30 | Author(s): Glenwood Goss
- Abstract
Loading... -
+
P3.01-044 - Erlotinib vs Chemotherapy in EGFR Mut+ NSCLC: OS in Three Phase III Trials Adjusting for Post-Progression Treatment Crossover
09:30 - 09:30 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P3.01-045 - Correlation of EGFR Mutation Detection in CtDNA by Two Different Platforms in Advanced NSCLC Patients from a Single Institution
09:30 - 09:30 | Author(s): N. Vilariño
- Abstract
Loading... -
+
P3.01-046 - Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab
09:30 - 09:30 | Presenter: Philip Christopher Mack
- Abstract
Loading... -
+
P3.01-047 - Erlotinib Induced Ectropion Followed by Papulo-Erythemato Skin Rash
09:30 - 09:30 | Presenter: Abdolali Shahrasbi
- Abstract
Loading... -
+
P3.01-048 - CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib
09:30 - 09:30 | Presenter: Lyudmila A Bazhenova
- Abstract
Loading... -
+
P3.01-049 - T790M Mutation Detection, Clinical Characteristics and Impact in NSCLC Patients Treated with EGFR Tyrosine Kinase Inhibitors
09:30 - 09:30 | Author(s): L. Bei
- Abstract
Loading... -
+
P3.01-050 - A Real World Treatment Study of Osimertinib: ASTRIS Study Korean Subgroup Analysis
09:30 - 09:30 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
P3.01-051 - Dramatic Response to Afatinib in EGFR-Mutant Lung Adenocarcinomas After Resistance to First-Generation EGFR Inhibitors: A Brief Report
09:30 - 09:30 | Presenter: Wen -Feng Li
- Abstract
Loading... -
+
P3.01-052 - The Prevalence and Genotype Distribution of Dual in Cis EGFR Mutations in Chinese Advanced Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Presenter: Min Li
- Abstract
Loading... -
+
P3.01-053 - Detection of Common EGFR Mutation in Cytological Smears Using Reversed Dot Blot (RDB) Hybridization Method
09:30 - 09:30 | Presenter: Najmiatul Masykura
- Abstract
Loading... -
+
P3.01-054 - Urinary ct-DNA Testing of EGFR Common Mutation in Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Presenter: Asep Muhamad Ridwanuloh
- Abstract
Loading... -
+
P3.01-055 - The Usefulness of Liquid Biopsy for ctDNA in Patients with EGFR-Mutant NSCLC During and After Treatment with EGFR-TKIs
09:30 - 09:30 | Presenter: Takuma Yokoyama
- Abstract
Loading... -
+
P3.01-056 - Intracranial Activity of Osimertinib in Naïve EGFRm T790M(-)And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
09:30 - 09:30 | Presenter: Nir Peled
- Abstract
Loading... -
+
P3.01-057 - Comparison of EGFR Mutations in Matched Tumor Tissues, Cell Blocks, Pleural Effusions and Bloods with NSCLC, by PANA Mutyper and PNA Clamping
09:30 - 09:30 | Presenter: Seung Joon Kim
- Abstract
Loading... -
+
P3.01-058 - Impact of Different Timing of Radiotherapy in Patients with Brain Metastases from Epidermal Growth Factor Receptor-Mutant NSCLC
09:30 - 09:30 | Presenter: Yaping Xu
- Abstract
Loading... -
+
P3.01-059 - First Experience with Osimertinib in Patients with Newly Developed T790M Mutation Previously Treated with EGFR – TKIs in Croatia
09:30 - 09:30 | Presenter: Marko Jakopovic
- Abstract
Loading... -
+
P3.01-060 - The Clinical Utility of ctDNA Gene Analysis in Lung Cancer
09:30 - 09:30 | Presenter: Smadar Geva
- Abstract
Loading... -
+
P3.01-061 - Endostar Combined with Re-Challenged Gefitinib in Previous Treatment Failed NSCLC: A Retrospective Study
09:30 - 09:30 | Presenter: Huijuan Wang
- Abstract
Loading... -
+
P3.01-062 - The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumour DNA T790M Testing
09:30 - 09:30 | Presenter: Tristan Alexandra Barnes
- Abstract
Loading... -
+
P3.01-063 - Concomitant EGFR Mutation and ALK Rearrangement in Non-Small-Cell Lung Cancer
09:30 - 09:30 | Presenter: Rui-Lian Chen
- Abstract
Loading... -
+
P3.01-064 - Detection of EGFR Mutations in Circulating Tumor DNA Using Plasma Samples: Clinical Validation of Cobas EGFR Mutation Test V2
09:30 - 09:30 | Presenter: Hidetoshi Itani
- Abstract
Loading... -
+
P3.01-065 - Advanced NSCLC with EGFR Mutations in Elderly Patients. Single-Centre Experience
09:30 - 09:30 | Presenter: Angel Artal Cortes
- Abstract
Loading... -
+
P3.01-066 - CNS Metastases of Pulmonary Adenocarcinoma Harboring EGFR-Activating Mutations: a Multidisciplinary Approach, Including EGFR-TKis
09:30 - 09:30 | Author(s): G. Harada
- Abstract
Loading... -
+
P3.01-067 - TP53 Mutations Could Involved in EGFR-TKI Primary Resistance in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): X. Li
- Abstract
Loading... -
+
P3.01-068 - Investigation of Low Plasma/Tissue EGFR Concordance in Russia: Follow-up to the IGNITE Global Diagnostic Study
09:30 - 09:30 | Presenter: Brian B Lentrichia
- Abstract
Loading... -
+
P3.01-069 - Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
09:30 - 09:30 | Presenter: Yun Fan
- Abstract
Loading... -
+
P3.01-070 - A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
09:30 - 09:30 | Presenter: Shun Lu
- Abstract
Loading... -
+
P3.01-071 - Randomized Phase 1b/3 Study of Erlotinib + Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes
09:30 - 09:30 | Presenter: Kazuhiko Nakagawa
- Abstract
Loading... -
+
P3.01-072 - Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)
09:30 - 09:30 | Presenter: Kazuhiko Nakagawa
- Abstract
Loading... -
+
P3.01-073 - TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
09:30 - 09:30 | Presenter: Rafael Rosell
- Abstract
Loading... -
+
P3.01-074 - Genomic Analysis of Tumor and Plasma in T790M Mutant Positive EGFR Lung Cancer Patients before and after Osimertinib Treatment
09:30 - 09:30 | Presenter: James Chih-Hsin Yang
- Abstract
Loading... -
+
P3.01-075 - Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC
09:30 - 09:30 | Presenter: Vera Hirsh
- Abstract
Loading... -
+
P3.01-076 - QTWiST Analysis to Compare the Benefit of Gefitinib Versus Pemetrexed Platinum for Patients with EGFR Mutated NSCLC
09:30 - 09:30 | Presenter: Vijay Patil
- Abstract
Loading... -
+
P3.01-076a - Lung Cancer Stem Cell (LCSC) Markers and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Resistance
09:30 - 09:30 | Presenter: Shinnosuke Takemoto
- Abstract
No abstract available for this presentation
-
+
P3.01-077 - Effectiveness of Methylnaltrexone Bromide in Opioid-Induced Constipation in Advanced NSCLC Patients
09:30 - 09:30 | Presenter: Ioannis Dimitroulis
- Abstract
Loading... -
+
P3.01-079 - Evaluating the Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Stage IIIa (N2) Lung Cancer
09:30 - 09:30 | Presenter: Luo-Sheng Yong
- Abstract
Loading... -
+
P3.01-080 - Overall Survival (OS) of Pathological N2 Non-Small Cell Lung Cancer (NSCLC) After Surgical Resection
09:30 - 09:30 | Presenter: Etienne Bourdages-Pageau
- Abstract
Loading... -
+
P3.01-081 - Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging
09:30 - 09:30 | Author(s): Etienne Bourdages-Pageau
- Abstract
Loading... -
+
P3.01-082 - Surgical Rebiopsy in Advanced Non-Small Cell Lung Cancer Resistant to Previous Chemotherapy
09:30 - 09:30 | Presenter: Sumin Shin
- Abstract
Loading... -
+
P3.01-083 - Clinical Characteristics and Survival Outcomes for Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations
09:30 - 09:30 | Presenter: Min Peng
- Abstract
Loading... -
+
P3.01-084 - Analysis on ALTER0303 Trial: aCECs Level May Correlate with Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC
09:30 - 09:30 | Author(s): Z. Liu
- Abstract
Loading... -
+
P3.01-085 - A Phase 2 Trial of Apatinib in Advanced Non-Squamous NSCLC: Updated Data and Clinical Benefit of Continuing Apatinib after Initial Progression
09:30 - 09:30 | Presenter: Fengying Wu
- Abstract
Loading... -
+
P3.01-086 - Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States
09:30 - 09:30 | Presenter: Laura Chu
- Abstract
Loading... -
+
P3.01-087 - Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303
09:30 - 09:30 | Presenter: Kai Li
- Abstract
Loading... -
+
P3.01-088 - Molecular Testing and First-Line Treatment of Patients with NSCLC. First Results from the German CRISP Study (AIO-TRK-0315)
09:30 - 09:30 | Author(s): Frank Griesinger
- Abstract
Loading... -
+
P3.01-088a - Phase II Study of Nab-Paclitaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: SNIPER Study
09:30 - 09:30 | Presenter: Naruo Yoshimura
- Abstract
Loading... -
+
P3.01-088b - Is Efficacy Result in Phase 2 Trial Replicated in Phase 3 Trial in Advanced NSCLC: A Meta-Analysis
09:30 - 09:30 | Presenter: R. Shibaki
- Abstract
Loading... -
+
P3.01-088c - Exosomal Amphiregulin Induce Osteoclastogenesis Through Osteoclast Differentiation Mediated by EGFR Pathway
09:30 - 09:30 | Presenter: Christian Rolfo
- Abstract
Loading... -
+
P3.01-088d - TTFields Combined with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC): Phase 3 LUNAR Study
09:30 - 09:30 | Presenter: Uri Weinberg
- Abstract
Loading... -
+
P3.01-088e - TTFields Delivery to the Brain: An Overview of Computational Studies and Implications When Treating Brain Metastases
09:30 - 09:30 | Author(s): S. Levi
- Abstract
Loading... -
+
P3.01-088f - Droplet Digital PCR-Based EGFR Mutation Detection with an Internal Quality Control Index to Determine the Quality of DNA
09:30 - 09:30 | Presenter: Sung Su Kim
- Abstract
Loading... -
+
P3.01-088g - Variation in Treatment Recommendations for NSCLC Patients by Multidisciplinary Tumor Board Meetings Across the Netherlands
09:30 - 09:30 | Author(s): O. Candiff
- Abstract
Loading... -
+
P3.01-088h - Resistance Mechanisms Causing First-line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment Failure
09:30 - 09:30 | Presenter: Chong-Kin Liam
- Abstract
Loading... -
+
P3.01-088i - Phase Ib Trial of Xentuzumab and Abemaciclib in Advanced or Metastatic Solid Tumors, including Advanced NSCLC
09:30 - 09:30 | Author(s): Douglas Yee
- Abstract
Loading... -
+
P3.01-088j - The Transitions of Prognostic Understanding and Its Associated Factors in Japanese Patients with Advanced Lung Cancer and Their Caregivers
09:30 - 09:30 | Presenter: Daisuke Arai
- Abstract
Loading... -
+
P3.01-088k - Significance of Second Rebiopsy for Detecting T790M Mutation
09:30 - 09:30 | Presenter: Eiki Ichihara
- Abstract
Loading...
-
+
P3.02 - Biology/Pathology
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 106
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.02-001 - Clinical Significance of Plasma Epstein-Barr Virus DNA in Pulmonary Lymphoepithelioma-Like Carcinoma (LELC) Patients
09:30 - 09:30 | Presenter: Mian Xie
- Abstract
Loading... -
+
P3.02-002 - Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients
09:30 - 09:30 | Author(s): D. Nunes
- Abstract
Loading... -
+
P3.02-003 - Tissue and Serum Levels of Galectin-3 in NSCLC Patients
09:30 - 09:30 | Presenter: Yoko Kataoka
- Abstract
Loading... -
+
P3.02-004 - Analysis of MET in Liquid Biopsy and Tissue Biopsy in Patients with Advanced NSCLC: Incidence and Pattern.
09:30 - 09:30 | Presenter: Edgardo S. Santos
- Abstract
Loading... -
+
P3.02-005 - Applicability of Ion Torrent Colon and Lung Sequencing Panel on Circulating Cell-Free DNA
09:30 - 09:30 | Presenter: Christina Demuth
- Abstract
Loading... -
+
P3.02-006 - Monitoring Genetic Alterations in Plasma during Anti-Cancer Treatment in Advanced NSCLC (MAGIC1-Validation Cohort: Preliminary Results)
09:30 - 09:30 | Presenter: Laura Bonanno
- Abstract
Loading... -
+
P3.02-007 - Circulating miRNAs as Prognostic Biomarkers in Resected Early-Stages Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): P. Ulivi
- Abstract
Loading... -
+
P3.02-008 - Non-Invasive Diagnosis of Solitary Pulmonary Nodules Using High-Throughput Targeted DNA Methylation Sequencing of Circulating Tumor DNA
09:30 - 09:30 | Presenter: Wenhua Liang
- Abstract
Loading... -
+
P3.02-009 - Mutation Detection in Cell-Free DNA from Patients with Lung Adenocarcinoma by Next-Generation Sequencing
09:30 - 09:30 | Presenter: Hana Khairina Putri Faisal
- Abstract
Loading... -
+
P3.02-010 - Significant Increase of Blood Extracellular Vesicles in Pulmonary Vein as Potential Prognostic Biomarker for Lung Cancer Patients
09:30 - 09:30 | Presenter: Byeon Hyeon Choi
- Abstract
Loading... -
+
P3.02-011 - A Prospective Study of Serial Circulating Tumor DNA Assessment in Detecting Recurrence of Resected Early-stage Lung Cancer
09:30 - 09:30 | Presenter: Hong Kwan Kim
- Abstract
Loading... -
+
P3.02-012 - Liquid Based Cytology (LBC) Specimens Were Useful for EGFR Mutation Test
09:30 - 09:30 | Presenter: Tatsuo Ohira
- Abstract
Loading... -
+
P3.02-013 - Prognostic Role of Circulating Tumor DNA (ctDNA) and Immune Cell Biomarkers in Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: Young Kwang Chae
- Abstract
Loading... -
+
P3.02-014 - Amplicon-Based Next-Generation Sequencing (NGS) of Plasma Cell-Free DNA (cfDNA) for Detection of Driver and Resistance Mutations in NSCLC
09:30 - 09:30 | Presenter: Nicolas Marie Guibert
- Abstract
Loading... -
+
P3.02-014a - Diagnostic Value of FR+-CTCs Detected by LT-PCR for Lung Cancer in SPN and Tumor Invasiveness in Adenocarcinoma (T≪3cm)
09:30 - 09:30 | Presenter: Qianjun Zhou
- Abstract
Loading... -
+
P3.02-015 - 433MHz Microwave Radiation Induces G2/M Checkpoint Arrest and Promotes Apoptosis under Hyperthermia in Non-Small Cell Lung Cancer Cells
09:30 - 09:30 | Presenter: Yanyan Zhao
- Abstract
Loading... -
+
P3.02-016 - Correlation of Programmed Cell Death Ligand-1 Messenger RNA and Protein Expression in Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Hyun Jung Kwon
- Abstract
Loading... -
+
P3.02-017 - Apoptosis-Related Protein in Non Small Cell Lung Cancer: Correlation of Clinicopathologic, Molecular Characteristics and Prognosis
09:30 - 09:30 | Presenter: Ping-Li Sun
- Abstract
Loading... -
+
P3.02-018 - Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report
09:30 - 09:30 | Author(s): W. Wang
- Abstract
Loading... -
+
P3.02-019 - Clinical Validation of a Real Time PCR Assay for the Detection of ROS1 Fusion in Chinese Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Guanshan Zhu
- Abstract
Loading... -
+
P3.02-020 - Comparison of Diagnostic Ability for EGFR Mutation of the Specimen Groups: Histology – Cytology – Plasma
09:30 - 09:30 | Presenter: Nguyen Son Lam
- Abstract
Loading... -
+
P3.02-021 - Secondary EGFR Exon 20 T790m Mutation for Therapy of Non Small Cell Lung Cancer at Phat Ngoc Thach - Ho Chi Minh City - Vietnam
09:30 - 09:30 | Presenter: Nguyen Son Lam
- Abstract
Loading... -
+
P3.02-022 - Protein Tyrosine Phosphatase Interacting Protein 51 Might Improve EGFR-TKI Sensitivity in Non-Small-Cell Lung Cancer
09:30 - 09:30 | Presenter: Xing Wang
- Abstract
Loading... -
+
P3.02-023 - Semaphorin 7A Reduces Response to EGFR-TKI Treatment via Apoptosis in Human Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Yuhei Kinehara
- Abstract
Loading... -
+
P3.02-024 - Role of FBXW7 in the Maintenance of Quiescent Cancer Stem Cells Resistant to Gefitinib in EGFR Mutation-Positive Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Moulid Hidayat
- Abstract
Loading... -
+
P3.02-025 - 65 Cases of Molecular Profiling Anaysis in Surgical Resected Pulmonary Neuroendocrine Carcinoma
09:30 - 09:30 | Author(s): Chunwei Xu
- Abstract
Loading... -
+
P3.02-026 - The Study of ROS1 Rearrangement in Advanced Primary Non-Small Cell Lung Cancer and Associated Metastatic Lesions
09:30 - 09:30 | Author(s): Chunwei Xu
- Abstract
Loading... -
+
P3.02-027 - Lung Adenocarcinoma Patient with EGFR 19 Exon Insert Mutation: I740_K745insIPVAIK and Its Response to Icotinib: A Case Report
09:30 - 09:30 | Author(s): Chunwei Xu
- Abstract
Loading... -
+
P3.02-028 - 276 Cases of EGFR/ALK Gene Status and Predominant Histologic Subtype in Chinese Surgically Resected Lung Adenocarcinoma
09:30 - 09:30 | Author(s): Z. Huang
- Abstract
Loading... -
+
P3.02-029 - 218 Cases of EGFR/ALK Gene Status Anaysis in Chinese Lung Squamous Cell Carcinoma
09:30 - 09:30 | Author(s): Chunwei Xu
- Abstract
Loading... -
+
P3.02-030 - Inhibitory Effects of Mitochondrial TRAP1 on Gefitinib-Resistance in Non-Small Lung Cancer Cells
09:30 - 09:30 | Presenter: Euntaik Jeong
- Abstract
Loading... -
+
P3.02-031 - Detection of Activating EGFR Mutations and Resistant T790M Mutation from cfDNA in Malignant Pleural Effusion(MPE-DNA)
09:30 - 09:30 | Presenter: Kirsty Wai Chung Lee
- Abstract
Loading... -
+
P3.02-032 - Spatial Heterogeneity of EGFR and KRAS Variant Allele Frequencies Correlates with Histological Patterns of Lung Adenocarcinomas
09:30 - 09:30 | Presenter: Steffen Dietz
- Abstract
Loading... -
+
P3.02-033 - Pathological and Molecular Alterations after First and Second Generation EGFR-TKI Therapy in Patients with EGFR-Mutated Lung Adenocarcinomas
09:30 - 09:30 | Presenter: Hironori Uruga
- Abstract
Loading... -
+
P3.02-034 - Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Wade Thomas Iams
- Abstract
Loading... -
+
P3.02-035 - Mutational Signatures and Their Association with Clinicopathological Features in Lung Adenocarcinoma of Smokers
09:30 - 09:30 | Presenter: Takayuki Honda
- Abstract
Loading... -
+
P3.02-036 - Feasibility Study to Evaluate Patterns of Metastases and Effect of Surgery on Lung Cancer Xenografts with Differing Sensitivity to EGFR TKI
09:30 - 09:30 | Presenter: Sabita Jiwnani
- Abstract
Loading... -
+
P3.02-038 - Diagnosis of Leptomeningeal Disease and Clonal Heterogeneity with Digital Droplet PCR (ddPCR) in EGFR Mutated NSCLC
09:30 - 09:30 | Presenter: Gareth Rivalland
- Abstract
Loading... -
+
P3.02-039 - Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S
09:30 - 09:30 | Presenter: Atsushi Osoegawa
- Abstract
Loading... -
+
P3.02-040 - Driver Gene Detection in Chinese NSCLC Patients Using cSMART and Prognosis Analysis
09:30 - 09:30 | Presenter: Xueqin Chen
- Abstract
Loading... -
+
P3.02-041 - EGFR Amplification Mediates Resistance to TAS121, A Third-Generation EGFR-TKI, in EGFR T790M-Positive Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Sho Watanabe
- Abstract
Loading... -
+
P3.02-042 - DS-1205b, a Novel, Selective, Inhibitor of AXL, Delays the Onset of Resistance and Overcomes Acquired Resistance to EGFR-TKIs
09:30 - 09:30 | Presenter: Takeshi Jimbo
- Abstract
Loading... -
+
P3.02-043 - Clinical and Genetic Features in Lung Adenocarcinoma Without EGFR Mutation and ALK Rearrangement in Taiwan
09:30 - 09:30 | Presenter: Tsu-Hui Shiao
- Abstract
Loading... -
+
P3.02-044 - Diagnosis and Monitoring of EGFR Mutation Status with cfDNA in Advanced NSCLC: A Prospective Single Institution Study in Asia
09:30 - 09:30 | Presenter: Teh-Ying Chou
- Abstract
Loading... -
+
P3.02-045 - Prevalence of ALK Gene Abnormalities in Routine Diagnostics of Polish NSCLC Patients
09:30 - 09:30 | Author(s): A. Grenda
- Abstract
Loading... -
+
P3.02-046 - EGFR-Grb2-GEP100 Complex Promoted Its Invasive and Metastatic Potential via Arf6 Pathway in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Toshi Menju
- Abstract
Loading... -
+
P3.02-047 - Testing EGFR and ALK in Large Cell Neuroendocrine Carcinoma of the Lung. Looking for Biological Features in Rare Tumors
09:30 - 09:30 | Presenter: Teresa García Manrique
- Abstract
Loading... -
+
P3.02-048 - Clinicopathologic Characteristics of Non-Small Cell Lung Carcinomas Habouring MET Exon 14 Skipping Mutations
09:30 - 09:30 | Presenter: Takeshi Fujii
- Abstract
Loading... -
+
P3.02-049 - The Evaluation of Circulating miRNA Expression in Plasma as the Epigenetic Marker of EGFR Mutation Status in NSCLC Patients
09:30 - 09:30 | Presenter: Mateusz Florczuk
- Abstract
Loading... -
+
P3.02-050 - Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell Lines
09:30 - 09:30 | Presenter: Anne Tranberg Madsen
- Abstract
Loading... -
+
P3.02-051 - Low Consistency Between FGFR1 Gene Amplification and Protein Expression in Squamous Cell Lung Cancer (SQCLC)
09:30 - 09:30 | Presenter: Joanna Chorostowska-Wynimko
- Abstract
Loading... -
+
P3.02-052 - Stability of EGFR Mutations in Whole Blood and Plasma in Patients with NSCLC
09:30 - 09:30 | Presenter: Johanne Andersen Højbjerg
- Abstract
Loading... -
+
P3.02-053 - Optimization and Characterization of Assays to Identify Met Exon 14 Skipping in FFPE Embedded NSCLC Samples
09:30 - 09:30 | Presenter: Steven G. Gray
- Abstract
Loading... -
+
P3.02-054 - Prognostic Implications of ROS1 Positivity in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Published Literature
09:30 - 09:30 | Presenter: Anchit Khanna
- Abstract
Loading... -
+
P3.02-055 - Detecting ALK, ROS1 and RET Gene Translocations in Non-Small Cell Lung Cancer (NSCLC) with the NanoString Platform
09:30 - 09:30 | Presenter: Hangjun Wang
- Abstract
Loading... -
+
P3.02-056 - EGFR Mutation Profile of NSCLC Patients Tested at the Lung Center of the Philippines
09:30 - 09:30 | Author(s): Francisco III Maramara Heralde
- Abstract
Loading... -
+
P3.02-057 - Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples
09:30 - 09:30 | Presenter: Kurtis D Davies
- Abstract
Loading... -
+
P3.02-058 - Detection of ROS1 Rearrangements in 508 Russian Patients with Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: Irina Demidova
- Abstract
Loading... -
+
P3.02-059 - T790M and C797S as Mechanisms of Acquired Resistance to Dacomitinib in Cell Models
09:30 - 09:30 | Presenter: Yoshihisa Kobayashi
- Abstract
Loading... -
+
P3.02-060 - EGFR Mutation Status by Three Sequencing Platforms in 704 Non-Small Cell Lung Cancer (NSCLC) Brazilian Patients
09:30 - 09:30 | Author(s): M. Corassa
- Abstract
Loading... -
+
P3.02-061 - An ALK Follow-On Companion Diagnostic Using CGP for Clinical Care of Patients with NSCLC
09:30 - 09:30 | Author(s): Y. Li
- Abstract
Loading... -
+
P3.02-062 - An EGFR Follow-On Companion Diagnostic for Clinical Care of Patients with NSCLC
09:30 - 09:30 | Author(s): Y. Li
- Abstract
Loading... -
+
P3.02-063 - EGFR Exon 20 Insertions in Lung Adenocarcinomas: Molecular and Clinicopathologic Characteristics Among Hispanics (Geno1.2-CLICaP)
09:30 - 09:30 | Author(s): Andrés F. Cardona
- Abstract
Loading... -
+
P3.02-064 - Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases
09:30 - 09:30 | Presenter: Takashi Inoue
- Abstract
Loading... -
+
P3.02-065 - Lung Adenocarcinoma Patient with EGFR Kinase Domain Duplication(KDD) and Its Response to Icotinib: A Case Report
09:30 - 09:30 | Author(s): W. Wang
- Abstract
Loading... -
+
P3.02-066 - Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Chiara Ambrogio
- Abstract
Loading... -
+
P3.02-067 - Lung Cancer with Concurrent EGFR Mutation and ROS1 Rearrangement: A Case Report
09:30 - 09:30 | Author(s): Y. Zhu
- Abstract
Loading... -
+
P3.02-068 - 95 Cases of EGFR/ALK Gene Status Anaysis in Lung Adenosquamous Carcinoma
09:30 - 09:30 | Author(s): Z. Xu
- Abstract
Loading... -
+
P3.02-069 - 58 Cases of EGFR/ALK Gene Status Anaysis in Pulmonary Sarcomatoid Carcinoma
09:30 - 09:30 | Author(s): Y. Huang
- Abstract
Loading... -
+
P3.02-070 - Investigation of Whether HIF-1α Inhibitors Can Increase EGFR-TKI Effect for Non-Small Cell Lung Cancer Cell Lines
09:30 - 09:30 | Presenter: Yung-Hung Luo
- Abstract
Loading... -
+
P3.02-071 - Statins May Improve the Prognosis of Patients with Lung Adenocarcinoma by Suppressing Mutant p53-Induced EMT
09:30 - 09:30 | Presenter: Shigeto Nishikawa
- Abstract
Loading... -
+
P3.02-072 - MiR-33b Inhibits Lung Adenocarcinoma Cell Epithelial-Mesenchymal Transition Through CeRNA Regulatory Network
09:30 - 09:30 | Author(s): Y.-. Tan
- Abstract
Loading... -
+
P3.02-073 - Stromal Hedgehog Pathway Activation Suppresses Growth and Metastasis of Lung Adenocarcinoma
09:30 - 09:30 | Author(s): S. Kasiri
- Abstract
Loading... -
+
P3.02-074 - Podoplanin-Positive CAF Is Associated with a Higher Number of Single Nucleotide Variants in Cancer Cells in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Shoko Nakasone
- Abstract
Loading... -
+
P3.02-075 - Molecular Disorders of the Genes of Intracellular Signal Pathways in Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Anna Shchayuk
- Abstract
Loading... -
+
P3.02-076 - Glutaminase Inhibitor CB-839 Radiosensitizes KRAS-Mutant Lung Cancer Cells in a LKB1- and KEAP1/NRF2-Pathway Dependent Manner
09:30 - 09:30 | Presenter: Piyada Sitthideatphaiboon
- Abstract
Loading... -
+
P3.02-077 - Platin Sensitivity and ATM-Deficiency in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): J. Moore
- Abstract
Loading... -
+
P3.02-078 - Establishing Malignant Pleural Mesothelioma Primary Cell Lines Using the 3D Spheroid Method Produces a Model with Better Tumour Architecture
09:30 - 09:30 | Presenter: Yuen Yee Cheng
- Abstract
Loading... -
+
P3.02-079 - A 3D Spheroid Culture Represents an Improved in Vitro Model of Malignant Plural Mesothelioma (MPM)
09:30 - 09:30 | Presenter: Yuen Yee Cheng
- Abstract
Loading... -
+
P3.02-080 - DNMT3A Defines a Unique Molecular Class of Chinese Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Author(s): Y. Zhu
- Abstract
Loading... -
+
P3.02-081 - Nutritional Status Assessment in Treatment Naïve Patients with Lung Cancer
09:30 - 09:30 | Presenter: Sabita Jiwnani
- Abstract
Loading... -
+
P3.02-082 - High Mobility Group Box 1 Antagonist Limits Metastatic Seeding in the Lungs via Reduction of Cell-Cel Adhesion
09:30 - 09:30 | Presenter: Adi Karsch-Bluman
- Abstract
Loading... -
+
P3.02-083 - DKK1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via β-Catenin Signaling Pathway
09:30 - 09:30 | Author(s): M. Jiang
- Abstract
Loading... -
+
P3.02-084 - FGF9-FGFR Pathway Induce Neuroendocrine Differentiation in Lung Epithelial Cells
09:30 - 09:30 | Presenter: Kota Ishioka
- Abstract
Loading... -
+
P3.02-085 - Sphingosine Kinase 1 (SPHK1) Promotes Proliferation and Survival in Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Nozomu Motono
- Abstract
Loading... -
+
P3.02-086 - MGA Suppresses the MYC Pathway in Lung Adeocarcinoma
09:30 - 09:30 | Presenter: Paula Llabata
- Abstract
Loading... -
+
P3.02-087 - Long Noncoding RNA FOXF1-AS1 Regulates Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
09:30 - 09:30 | Presenter: Yongsheng Wang
- Abstract
Loading... -
+
P3.02-088 - Enhanced Glycolysis Is Critical for Maintaining Inactivation of JNK and Stability of EGFR Leading to the Survival of EGFR-Mutant Lung Cancer Cells
09:30 - 09:30 | Presenter: Jae Cheol Lee
- Abstract
Loading... -
+
P3.02-089 - Establishment of Highly Metastatic Lung Cancer Cell Sublines in Long-term Three-dimensional Low Attachment Cultures
09:30 - 09:30 | Presenter: Tomoyuki Nakano
- Abstract
Loading... -
+
P3.02-090 - Hypoxia-Induced Modifications of the Small Non-Coding RNA Transcriptome Delineates Risk of Recurrence in Early-Stage Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Victor D Martinez
- Abstract
Loading... -
+
P3.02-091 - Concurrent Aberrations in G2/M-Phase Transcriptional Programs and Genomic Gatekeepers Highlight Lung Cancer Predisposition in COPD Patients
09:30 - 09:30 | Presenter: Erin Anne Marshall
- Abstract
Loading... -
+
P3.02-092 - CD151-Integrin-C-Kit Axis Plays an Important Role in the Pathogenesis of Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Zeyi Liu
- Abstract
Loading... -
+
P3.02-093 - Knockdown of BRM Causes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cell Line H1975
09:30 - 09:30 | Presenter: Daisuke Matsubara
- Abstract
Loading... -
+
P3.02-094 - Identification of Oncofetal piRNAs in Lung
09:30 - 09:30 | Presenter: Brenda C. Minatel
- Abstract
Loading... -
+
P3.02-095 - Basic Transcription Factor 3 Is Involved in Lung Cancer Growth and Progression
09:30 - 09:30 | Author(s): S. Xu
- Abstract
Loading... -
+
P3.02-096 - The Interaction Between Mast Cells and Lung Cancer Cells Through Extracellular Vesicles
09:30 - 09:30 | Presenter: Smadar Geva
- Abstract
Loading... -
+
P3.02-097 - Clinicopathological Features and Genetic Landscape of Pulmonary Large Cell Carcinoma under 2015 WHO Classification of NSCLC
09:30 - 09:30 | Presenter: Renwang Liu
- Abstract
Loading... -
+
P3.02-097a - Metabolic Biomarkers in Serum for the Early Diagnosis of Lung Cancer: First Results from the Cancer-Biomarkers in HUNT Initiative
09:30 - 09:30 | Presenter: Oluf Dimitri Røe
- Abstract
Loading... -
+
P3.02-097b - Significance of PAK1/CREB Pathway in Lung Adenocarcinoma Oncogenesis
09:30 - 09:30 | Presenter: S.H. Yoon
- Abstract
Loading... -
+
P3.02-097c - Detection of the EGFR P.(T790M) Mutation by Different Methods: A Small Comparison Case Study
09:30 - 09:30 | Presenter: Hangjun Wang
- Abstract
Loading... -
+
P3.02-097d - Pulmonary LCNEC Might Be Aggregated With SCC On the Basis of Different Clinical Features, Overall Survival, and Pathogenesis
09:30 - 09:30 | Presenter: Ke Chen
- Abstract
Loading... -
+
P3.02-097e - Prognostic Importance of Tumor Spread Through Air Spaces in Lymph Node Negative Operated Adenocarcinoma Lung Cancers
09:30 - 09:30 | Presenter: F.S. Biricik
- Abstract
Loading... -
+
P3.02-097f - Rare Actionable Mutations in a Lung Adenocarcinoma Cohort in Brazil
09:30 - 09:30 | Presenter: C.G. Ferreira
- Abstract
Loading... -
+
P3.02-097g - LRIG1 and LMO7 Are Interacting Proteins with Clinical Significance in NSCLC
09:30 - 09:30 | Presenter: Samuel Kvarnbrink
- Abstract
Loading... -
+
P3.02-097h - Mutational Analysis of Multiple Lung Cancers: Discrimination between Primary and Metastatic Lung Cancers by Genomic Profile
09:30 - 09:30 | Presenter: Taichiro Goto
- Abstract
Loading... -
+
P3.02-097i - Neutrophil to Lymphocyte Ratio may be a Prognostic Factor in Advanced Stage Lung Cancer Patients
09:30 - 09:30 | Presenter: Bülent Karagöz
- Abstract
Loading...
first
prev
